DRL launches Vozat Tablets in Indian markets

Image
Press Trust of India Hyderabad
Last Updated : Jul 18 2017 | 7:28 PM IST
Dr. Reddy's Laboratories (DRL) today said it launched Vozet Tablets in Indian market. The drug is indicated for the treatment of allergic Rhinitis and chronic Urticaria.
According to a press release issued by the city-based drug maker, Vozet Tablets contain Levocetirizine 5 mg, and are available in a strip size of 10 tablets.
The anti-histamine market in India had sales of Rs 1,038 crore MAT for the most recent twelve months ended in March 2017, according to IMS data.
Dr. Reddy's will further strengthen its anti-allergy portfolio with the addition of Vozet, it added.
DR Reddy's shares closed at Rs 2715.65 on BSE up 0.83 per cent compared to previous close even as the benchmark sensex closed at 31710.99 points down 1.13 per cent.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 18 2017 | 7:28 PM IST

Next Story